Patel, Dipak R.
Macpherson, Lisa
Bohm, Martin
Upadhyaya, Himanshu
Deveau, Carmen
Nirula, Ajay
Klekotka, Paul
Williams, Mark
Hufford, Matthew M.
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 13 May 2024
Accepted: 5 August 2024
First Online: 4 September 2024
Declarations
:
: Dipak R. Patel, Lisa Macpherson, Martin Bohm, Carmen Deveau, Paul Klekotka, Mark Williams, and Matthew M. Hufford are employees and/or stockholders of Eli Lilly and Company. Himanshu Upadhyaya was an employee at Eli Lilly and Company at the time of study and development of the manuscript and is currently employed by Supernus Pharmaceuticals, Inc. Rockville, Maryland, USA. Ajay Nirula was an employee at Eli Lilly and Company at the time of study and development of the manuscript and is currently employed by Recludix Pharma, San Diego, California, USA.
: The study was conducted in accordance with the principles of the Declaration of Helsinki (2000), the International Conference on Harmonization, and the E6 Guideline for Good Clinical Practice. Institutional review board approval and written informed consent from all subjects were obtained before the conduct of any evaluations or study procedures.
: All authors have given their consent and approval of the final version to be submitted and published.